Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Cancer symbols : Alpmy save search
Astellas' XTANDI™ (Enzalutamide) Granted European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment Setting
Published: 2024-04-23 (Crawled : 00:00) - prnewswire.com
ALPMY | News | $9.49 -0.42% 55K
|
Manufacturing
| Email alert
Add to watchlist
ALPMF | News | $9.5 -2.56% 21K
|
Health Technology
| Email alert
Add to watchlist
TAK | News | $13.38 0.15% -0.67% 2.9K
|
Health Technology
| Email alert
Add to watchlist
granted approval cancer treatment for
China's National Medical Products Administration Accepts Astellas and Pfizer's Supplemental Biologics License Application for enfortumab vedotin with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
Published: 2024-03-28 (Crawled : 15:00) - prnewswire.com
ALPMY | News | $9.49 -0.42% 55K
|
Manufacturing
|
| O: 0.82%
H: 0.0%
C: -2.54%
keytruda license bladder cancer treatment medical application advanced
Astellas' VYLOY™ (zolbetuximab) Approved in Japan for Treatment of Gastric Cancer
Published: 2024-03-26 (Crawled : 12:00) - prnewswire.com
ALPMY | News | $9.49 -0.42% 55K
|
Manufacturing
|
| O: -1.65%
H: 3.36%
C: 3.17%
japan approved cancer treatment
Astellas Receives Positive CHMP Opinion for XTANDI™ in Additional Recurrent Early Prostate Cancer Treatment Setting
Published: 2024-03-22 (Crawled : 12:00) - prnewswire.com
ALPMF | News | $9.5 -2.56% 21K
|
Health Technology
|
| O: -0.54%
H: 0.0%
C: 0.0%
ALPMY | News | $9.49 -0.42% 55K
|
Manufacturing
|
| O: 2.26%
H: 0.0%
C: -2.65%
chmp positive cancer treatment
Non-Small Cell Lung Cancer (NSCLC) Market to Reach $29.95 Billion by 2028, Fueled by Advances in Therapy and Diagnostics
Published: 2024-02-22 (Crawled : 01:00) - prnewswire.com
GLAXF | News | $19.54 -3.77% 0
|
Health Technology
|
| O: 0.14%
H: 0.0%
C: -0.0%
SNYNF | News | $94.25 1.67% -2.18% 0
|
Health Technology
|
| O: 0.26%
H: 1.36%
C: 1.36%
AZNCF | News | $140.3 1.13% 0
|
Health Technology
|
| O: -0.85%
H: 1.12%
C: 0.43%
NVSEF | News | $96.0 0.94% 0
|
Health Technology
|
| O: 0.92%
H: 0.0%
C: 0.0%
UCBJY | $65.26 0.51% -4.38% 0
|
Manufacturing
|
| O: 1.46%
H: 0.44%
C: 0.44%
ALPMY | News | $9.49 -0.42% 55K
|
Manufacturing
|
| O: -0.27%
H: 0.0%
C: -1.17%
TAK | News | $13.38 0.15% -0.67% 2.9K
|
Health Technology
|
| O: -0.2%
H: 0.14%
C: -0.48%
NVS | News | $97.28 2.27% 1.47% 190K
|
Health Technology
|
| O: -0.06%
H: 0.46%
C: 0.29%
GSK | News | $41.24 1.6% 0.0% 1.6K
|
Health Technology
|
| O: -0.69%
H: 1.42%
C: 1.22%
LLY | News | $745.69 1.96% 0.04% 4K
|
Health Technology
|
| O: 2.37%
H: 1.51%
C: 0.79%
BMY | $48.72 -0.55% 250K
|
Health Technology
|
| O: -0.65%
H: 1.63%
C: 1.48%
ABBV | News | $168.48 -0.63% 110K
|
Health Technology
|
| O: -0.88%
H: 1.46%
C: 1.13%
SNY | News | $47.69 1.15% 1.13% 1.1K
|
Health Technology
|
| O: 1.67%
H: 0.0%
C: 0.0%
AZN | News | $71.19 0.48% 1M
|
Health Technology
|
| O: -2.81%
H: 2.08%
C: 1.38%
AMGN | News | $270.69 -1.04% 120K
|
Health Technology
|
| O: -0.35%
H: 1.15%
C: 0.96%
lung reach cancer cell diagnostics therapy market
PADCEV™ (enfortumab vedotin (genetical recombination)) with KEYTRUDA® (pembrolizumab (genetical recombination)) Granted Priority Review by Japan's Ministry of Health, Labour and Welfare for First-Line Treatment of Advanced Bladder Cancer
Published: 2024-02-15 (Crawled : 00:00) - prnewswire.com
ALPMY | News | $9.49 -0.42% 55K
|
Manufacturing
|
| O: -2.99%
H: 3.82%
C: 3.54%
keytruda granted review bladder cancer treatment advanced
Blood Cancer Drugs Market Report 2023: Reveals Striking Growth Prospects with a Surge in R&D Activities - Long-term Forecasts to 2028 and 2033
Published: 2024-02-06 (Crawled : 00:00) - prnewswire.com
ALPMF | News | $9.5 -2.56% 21K
|
Health Technology
|
| O: -1.53%
H: 0.0%
C: 0.0%
AZNCF | News | $140.3 1.13% 0
|
Health Technology
|
| O: -0.37%
H: 0.0%
C: 0.0%
NVSEF | News | $96.0 0.94% 0
|
Health Technology
|
| O: 0.41%
H: 0.0%
C: 0.0%
UCBJY | $65.26 0.51% -4.38% 0
|
Manufacturing
|
| O: 1.71%
H: 1.28%
C: 0.94%
ALPMY | News | $9.49 -0.42% 55K
|
Manufacturing
|
| O: 0.28%
H: 0.18%
C: 0.0%
TAK | News | $13.38 0.15% -0.67% 2.9K
|
Health Technology
|
| O: 0.07%
H: 0.42%
C: 0.07%
NVS | News | $97.28 2.27% 1.47% 190K
|
Health Technology
|
| O: 0.09%
H: 0.39%
C: -0.36%
JNJ | News | $149.56 0.3% 0.03% 140K
|
Health Technology
|
| O: 1.47%
H: 0.0%
C: 0.0%
LLY | News | $745.69 1.96% 0.04% 4K
|
Health Technology
|
| O: 0.76%
H: 4.31%
C: 2.11%
BMY | $48.72 -0.55% 250K
|
Health Technology
|
| O: -0.14%
H: 0.35%
C: -1.12%
ABBV | News | $168.48 -0.63% 110K
|
Health Technology
|
| O: 1.48%
H: 0.0%
C: 0.0%
VRTX | $404.91 1.25% 1.43% 1.8K
|
Health Technology
|
| O: 0.15%
H: 2.4%
C: 0.56%
SNY | News | $47.69 1.15% 1.13% 1.1K
|
Health Technology
|
| O: 1.33%
H: 0.0%
C: 0.0%
JAZZ | $109.67 0.77% 0.78% 100
|
Health Technology
|
| O: -0.02%
H: 0.0%
C: -1.4%
AZN | News | $71.19 0.48% 1M
|
Health Technology
|
| O: -0.4%
H: 0.19%
C: -0.33%
AMGN | News | $270.69 -1.04% 120K
|
Health Technology
|
| O: -0.18%
H: 0.0%
C: -6.22%
report cancer blood growth market
Astellas Submits Supplemental New Drug Application in Japan for PADCEV™ (enfortumab vedotin (genetical recombination)) with KEYTRUDA® (pembrolizumab (genetical recombination)) for First-Line Treatment of Advanced Bladder Cancer
Published: 2024-01-31 (Crawled : 02:00) - prnewswire.com
ALPMF | News | $9.5 -2.56% 21K
|
Health Technology
|
| O: 4.34%
H: 0.0%
C: 0.0%
ALPMY | News | $9.49 -0.42% 55K
|
Manufacturing
|
| O: 0.0%
H: 1.38%
C: 0.26%
PFE | News 4 | $26.32 0.23% 0.15% 88K
|
Health Technology
|
| O: 0.56%
H: 1.25%
C: -0.33%
keytruda drug japan bladder cancer treatment application advanced
European Medicines Agency Validates Type II Variation Application for PADCEV™ (enfortumab vedotin) with KEYTRUDA®(pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
Published: 2024-01-26 (Crawled : 17:00) - prnewswire.com
ALPMF | News | $9.5 -2.56% 21K
|
Health Technology
|
| O: -6.38%
H: 0.88%
C: 0.88%
ALPMY | News | $9.49 -0.42% 55K
|
Manufacturing
|
| O: 0.09%
H: 0.17%
C: -0.3%
PFE | News 4 | $26.32 0.23% 0.15% 88K
|
Health Technology
|
| O: 0.58%
H: 1.01%
C: -0.58%
keytruda bladder cancer treatment application advanced
Castration-Resistant Prostate Cancer (CRPC) Treatment Market size to grow by USD 5.98 billion from 2023 to 2028, North America to account for 47% of market growth- Technavio
Published: 2024-01-09 (Crawled : 03:00) - prnewswire.com
ALPMF | News | $9.5 -2.56% 21K
|
Health Technology
|
| O: 0.16%
H: 0.0%
C: -3.88%
NVSEF | News | $96.0 0.94% 0
|
Health Technology
|
| O: -0.24%
H: 0.0%
C: 0.0%
ALPMY | News | $9.49 -0.42% 55K
|
Manufacturing
|
| O: -1.22%
H: 0.0%
C: -0.72%
NVS | News | $97.28 2.27% 1.47% 190K
|
Health Technology
|
| O: -0.46%
H: 0.74%
C: -0.19%
SNY | News | $47.69 1.15% 1.13% 1.1K
|
Health Technology
|
| O: 0.74%
H: 0.0%
C: 0.0%
AMGN | News | $270.69 -1.04% 120K
|
Health Technology
|
| O: -0.92%
H: 0.63%
C: -0.25%
america cancer treatment market
PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) Approved by FDA as the First and Only ADC Plus PD-1 to Treat Advanced Bladder Cancer
Published: 2023-12-15 (Crawled : 22:00) - prnewswire.com
PFE | News 4 | $26.32 0.23% 0.15% 88K
|
Health Technology
| Email alert
Add to watchlist
ALPMF | News | $9.5 -2.56% 21K
|
Health Technology
| Email alert
Add to watchlist
ALPMY | News | $9.49 -0.42% 55K
|
Manufacturing
| Email alert
Add to watchlist
padcev fda first approved bladder cancer treat advanced plus
FDA Grants Priority Review for Supplemental Biologics License Application (sBLA) of PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
Published: 2023-11-30 (Crawled : 22:00) - prnewswire.com
ALPMF | News | $9.5 -2.56% 21K
|
Health Technology
|
| O: 3.87%
H: 0.0%
C: 0.0%
ALPMY | News | $9.49 -0.42% 55K
|
Manufacturing
|
| O: -3.37%
H: 4.51%
C: 4.51%
PFE | News 4 | $26.32 0.23% 0.15% 88K
|
Health Technology
|
| O: -4.92%
H: 1.48%
C: -0.21%
padcev fda license review bladder cancer treatment application grants
Pfizer and Astellas' XTANDI® Approved by U.S. FDA in Earlier Prostate Cancer Treatment Setting
Published: 2023-11-17 (Crawled : 04:00) - prnewswire.com
ALPMF | News | $9.5 -2.56% 21K
|
Health Technology
|
| O: 0.04%
H: 0.0%
C: 0.0%
ALPMY | News | $9.49 -0.42% 55K
|
Manufacturing
|
| O: 1.38%
H: 1.79%
C: 1.79%
PFE | News 4 | $26.32 0.23% 0.15% 88K
|
Health Technology
|
| O: 0.5%
H: 0.3%
C: 0.0%
xtandi fda approved cancer treatment
Kadcyla Leads the Global Antibody Drug Conjugates Market with Extensive Use in Breast Cancer Treatment
Published: 2023-11-01 (Crawled : 18:00) - prnewswire.com
ALPMY | News | $9.49 -0.42% 55K
|
Manufacturing
|
| O: -1.46%
H: 3.67%
C: 3.26%
ZYME | $8.56 2.1K
|
Health Technology
|
| O: 1.14%
H: 0.42%
C: -0.7%
TAK | News | $13.38 0.15% -0.67% 2.9K
|
Health Technology
|
| O: 1.03%
H: 0.73%
C: 0.58%
ADCT | $4.97 1.1K
|
Health Technology
|
| O: -0.16%
H: 6.42%
C: 4.49%
ABBV | News | $168.48 -0.63% 110K
|
Health Technology
|
| O: -0.86%
H: 0.0%
C: 0.0%
STRO | $3.72 -1.33% -1.07% 1.6K
|
Health Technology
|
| O: 0.39%
H: 3.86%
C: 3.86%
IMGN | News | $31.23 0.03% 49M
|
Health Technology
|
| O: 5.09%
H: 5.48%
C: -1.27%
GILD | $66.45 -0.87% 380K
|
Health Technology
|
| O: -0.47%
H: 1.88%
C: 1.78%
EXEL | $23.38 0.39% 43K
|
Health Technology
|
| O: -2.62%
H: 1.17%
C: -1.66%
drug antibody breast cancer treatment global market
Groundbreaking EV-302 Trial Significantly Extends Overall Survival and Progression-Free Survival in Patients Treated with PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) in First-Line Advanced Bladder Cancer
Published: 2023-10-22 (Crawled : 16:20) - prnewswire.com
ALPMF | News | $9.5 -2.56% 21K
|
Health Technology
| Email alert
Add to watchlist
SGEN | $228.74 0.1% 20M
|
Health Technology
| Email alert
Add to watchlist
ALPMY | News | $9.49 -0.42% 55K
|
Manufacturing
| Email alert
Add to watchlist
ev-302 padcev bladder cancer trial
PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) Significantly Improve Overall Survival and Progression-Free Survival in Patients With Previously Untreated Advanced Bladder Cancer in Pivotal Phase 3 EV-302 Trial
Published: 2023-09-22 (Crawled : 09:00) - prnewswire.com
ALPMY | News | $9.49 -0.42% 55K
|
Manufacturing
|
| O: -0.56%
H: 1.48%
C: 1.12%
SGEN | $228.74 0.1% 20M
|
Health Technology
|
| O: 3.59%
H: 0.09%
C: -0.05%
ev-302 padcev bladder cancer trial
European Medicines Agency Validates Type II Variation for Astellas' XTANDI® (enzalutamide) for Treatment of Non-Metastatic Hormone-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence
Published: 2023-09-12 (Crawled : 00:00) - prnewswire.com
ALPMY | News | $9.49 -0.42% 55K
|
Manufacturing
|
| O: -0.03%
H: 1.04%
C: -0.37%
PFE | News 4 | $26.32 0.23% 0.15% 88K
|
Health Technology
|
| O: 0.18%
H: 1.2%
C: -0.38%
xtandi cancer treatment
FDA Grants Priority Review for XTANDI® in Non-Metastatic Castration-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence
Published: 2023-08-23 (Crawled : 12:00) - biospace.com/
ALPMY | News | $9.49 -0.42% 55K
|
Manufacturing
|
| O: 0.59%
H: 0.46%
C: 0.46%
PFE | News 4 | $26.32 0.23% 0.15% 88K
|
Health Technology
|
| O: 0.68%
H: 0.11%
C: -1.16%
xtandi fda review cancer grants
Bladder Cancer Market Likely to Exhibit Substantial Growth, Assesses DelveInsight | Leading Companies - CicloMed, Bristol-Myers Squibb, CG Oncology, Merck, Eli Lilly and Company, UroGen, Ferring
Published: 2023-08-07 (Crawled : 21:00) - prnewswire.com
ALPMY | News | $9.49 -0.42% 55K
|
Manufacturing
|
| O: 0.19%
H: 0.0%
C: -2.72%
LLY | News | $745.69 1.96% 0.04% 4K
|
Health Technology
|
| O: 11.43%
H: 6.32%
C: 3.08%
URGN | $14.53 1.11% 0.96% 0
|
Health Technology
|
| O: -1.3%
H: 6.76%
C: 5.57%
INCY | $51.65 -0.52% -0.58% 11
|
Health Technology
|
| O: 2.58%
H: 0.41%
C: -1.13%
FUSN | $21.4 -0.09% 38K
|
Health Technology
|
| O: 10.6%
H: 0.0%
C: -9.58%
companies bladder cancer market
Astellas and Poseida Therapeutics Announce Strategic Investment to Support Poseida's Commitment to Redefining Cancer Cell Therapy
Published: 2023-08-07 (Crawled : 13:00) - prnewswire.com
ALPMF | News | $9.5 -2.56% 21K
|
Health Technology
|
| O: 9.22%
H: 0.0%
C: -0.32%
ALPMY | News | $9.49 -0.42% 55K
|
Manufacturing
|
| O: 11.06%
H: 0.0%
C: -0.39%
PSTX | $2.16 0.23% -0.23% 0
|
Health Technology
|
| O: 32.52%
H: 24.54%
C: -8.33%
cancer cell therapeutics therapy
Gainers vs Losers
| 71% | 29% |
Top 10 Gainers
CZOO | $9.98 100.0% 330K
|
AMST | $3.48 74.0% 21M
|
Technology Services
BOF | $1.78 52.14% 15M
|
CSSE 4 | $0.2184 43.4% 36M
|
Consumer Services
ACB | $7.32 16.56% 780K
|
Process Industries
AEYE | $15.42 14.39% 150K
|
Technology Services
BACK | $3.75 13.64% 44K
|
Health Care and Social Assistan...
CGC | $8.835 12.55% 740K
|
Process Industries
BW | News | $1.0002 9.05% 190K
|
Electronic Technology
BILI | $12.525 9.01% 3.5M
|
Technology Services
Your saved searches
Save your searches and get alerts when important news are released.